Literature DB >> 20216401

PAX-2 expression in non-neoplastic, primary neoplastic, and metastatic neoplastic tissue: A comprehensive immunohistochemical study.

Qihui Jim Zhai1, Ayhan Ozcan, Candice Hamilton, Steven S Shen, Donna Coffey, Bhuvaneswari Krishnan, Luan D Truong.   

Abstract

PAX-2 is a transcription factor that controls the development of the kidney, organs deriving from the mesonephric (Wolffian) duct, and those related to the Müllerian duct. Although PAX-2 is shown to be a sensitive marker for tumors derived from these organs, but whether it is specific, that is, whether other tumor types also express PAX-2, has not been systematically evaluated in either primary or metastatic tumors. Tissue sections from 937 normal or reactive tissue samples, 759 primary neoplasms, and 332 metastatic neoplasms were submitted to PAX-2 immunostain. Among the non-neoplastic tissue, PAX-2 was expressed in glomerular parietal epithelial cells, renal collecting duct cells, atrophic renal tubular cells, epithelial cells of ovarian surface, fallopian tube, endocervix, endometrium, seminal vesicle, and lymphocytes. Among the primary neoplasms, PAX-2 was noted in 104/122 (85%) of renal cell carcinoma, 31/95 carcinomas of Müllerian origin, 17/17 (100%) lymphomas, 4/4 (100%) nephrogenic adenomas, and 1/16 (6%) benign parathyroid tumors, but was negative in 477 other tumors. Among the metastatic tumors, PAX-2 was noted in 70/95 (74%) metastatic renal cell carcinomas, 14/20 (70%) metastatic tumors of Müllerian origin, 1/20 (5%) metastatic colon carcinoma of lymph nodes, 1/62 (2%) metastatic breast carcinoma of lymph nodes, but was not seen in the remaining 247 metastatic tumors. PAX-2 expression in non-neoplastic mature tissue is limited to the organs whose embryonic development depends on this transcription factor. PAX-2 is a sensitive and specific marker for tumors of renal or Müllerian origin in both primary and metastatic contexts.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20216401     DOI: 10.1097/PAI.0b013e3181d712ef

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  14 in total

Review 1.  Water-clear parathyroid adenoma: report of two cases and literature review.

Authors:  Shuting Bai; Virginia A LiVolsi; Douglas L Fraker; Zhanyong Bing
Journal:  Endocr Pathol       Date:  2012-09       Impact factor: 3.943

Review 2.  Are Pax proteins potential therapeutic targets in kidney disease and cancer?

Authors:  Edward Grimley; Gregory R Dressler
Journal:  Kidney Int       Date:  2018-04-21       Impact factor: 10.612

3.  Gene expression profiling reveals differentially expressed genes in ovarian cancer of the hen: support for oviductal origin?

Authors:  Lindsey S Treviño; James R Giles; Wei Wang; Mary Ellen Urick; Patricia Ann Johnson
Journal:  Horm Cancer       Date:  2010-08       Impact factor: 3.869

4.  Emerging relationships between papillary proliferation of the endometrium and endometrial carcinoma: evidence from an immunohistochemical and molecular analysis.

Authors:  Qin Liu; Qiongyan Wu; Minghua Yu; Haiyan Shi; Bingjian Lu
Journal:  Virchows Arch       Date:  2019-05-12       Impact factor: 4.064

5.  Identification of Pax protein inhibitors that suppress target gene expression and cancer cell proliferation.

Authors:  Shayna T J Bradford; Edward Grimley; Ann M Laszczyk; Pil H Lee; Sanjeevkumar R Patel; Gregory R Dressler
Journal:  Cell Chem Biol       Date:  2021-11-24       Impact factor: 8.116

6.  Evaluation of PAX2 and PAX8 expression in salivary gland neoplasms.

Authors:  Randall T Butler; Megan A Alderman; Lester D R Thompson; Jonathan B McHugh
Journal:  Head Neck Pathol       Date:  2014-04-26

Review 7.  The emergence of the glomerular parietal epithelial cell.

Authors:  Stuart J Shankland; Bart Smeets; Jeffrey W Pippin; Marcus J Moeller
Journal:  Nat Rev Nephrol       Date:  2014-01-28       Impact factor: 28.314

8.  Diagnostic utility of E-cadherin and P120 catenin cocktail immunostain in distinguishing DCIS from LCIS.

Authors:  Xiaoxian Li; Mary R Schwartz; Jae Ro; Candice R Hamilton; Alberto G Ayala; Luan D Truong; Qihui Jim Zhai
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

9.  PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.

Authors:  D Ates Ozdemir; A Usubutun
Journal:  Pathol Oncol Res       Date:  2016-01-21       Impact factor: 3.201

10.  Association between graves' disease and renal coloboma syndrome: a case report.

Authors:  Takeshi Sato; Koji Muroya; Junko Hanakawa; Yumi Asakura; Eihiko Takahashi; Yoshiyuki Shiroyanagi; Yuichiro Yamazaki; Yukichi Tanaka; Tomonobu Hasegawa; Masanori Adachi
Journal:  Clin Pediatr Endocrinol       Date:  2013-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.